SCHEMBL4344613

SCHEMBL4344613

NC(=S)NN=Cc1ccc(N2CCN(Cc3ccccc3Cl)CC2)c(F)c1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
KDM4E B2RXH2 5/20 0.48
PLA2G1B P04054 1/20 0.48
RAB9A P51151 1/20 0.48
ATG4B Q9Y4P1 1/20 0.48
MAPT P10636 7/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
HTT P42858 3/20 0.43
KMT2A Q03164 2/20 0.43
MAOB P27338 1/20 0.42
POLB P06746 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
GAA P10253 3/20 0.41
PKM P14618 1/20 0.40
MAPK1 P28482 1/20 0.40
MEN1 O00255 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
LMNA P02545 1/20 0.39
NPY2R P49146 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4344610 1.00 ALDH1A1 (0.48) ALDH1A1KDM4EPLA2G1BRAB9AATG4B
SCHEMBL4459405 0.90 MAOB (0.49) ALDH1A1KDM4ERAB9AMAPTSMN1; SMN2
SCHEMBL4459407 0.90 MAOB (0.49) ALDH1A1KDM4ERAB9AMAPTSMN1; SMN2
SCHEMBL6442935 0.89 MAPT (0.42) ALDH1A1KDM4EMAPTSMN1; SMN2TDP1
SCHEMBL4451957 0.89 MAPT (0.42) ALDH1A1KDM4EMAPTSMN1; SMN2TDP1
SCHEMBL4335442 0.89 MAOB (0.42) ALDH1A1KDM4ERAB9AMAPTTDP1
SCHEMBL4335444 0.89 MAOB (0.42) ALDH1A1KDM4ERAB9AMAPTTDP1
SCHEMBL4322538 0.88 L3MBTL1 (0.49) ALDH1A1KDM4ERAB9AKMT2AMAOB
SCHEMBL4322537 0.88 L3MBTL1 (0.49) ALDH1A1KDM4ERAB9AKMT2AMAOB
SCHEMBL4327626 0.87 TDP1 (0.43) ALDH1A1KDM4ERAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 ALDH1A1 1459/4885KDM4E 3010/4885PLA2G1B 4146/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 ALDH1A1 1173/4885KDM4E 2338/4885PLA2G1B 3881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.